Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes.
点击次数:
所属单位:
Central South University
教研室:
Xiang-Ya School of Medicine
发表刊物:
Br J Clin Pharmacol.
刊物所在地:
british
项目来源:
National Natural Science Foundation of China Grants 30572230 and 30873089
关键字:
ADRB3, genetic polymorphism, rosiglitazone, Type 2 diabetes, UCP2
摘要:
Abstract
AIMS:
The aim of this study was to explore the impact of UCP2 and ADRB3 genetic polymorphisms on the therapeutic efficacy of rosiglitazone in Chinese Type 2 diabetes (T2DM) patients.
METHODS:
A total of 199 T2DM patients and 155 healthy volunteers were enrolled to identify UCP2 -866 G/A genotypes, and 273 T2DM patients and 166 controls were genotyped for Trp64Arg of ADRB3 by polymerase chain reaction-restriction fragment length polymorphism assay. Nine patients with GG genotype and 27 with GA+AA genotype of UCP2 -866 G/A, 11 with Trp64Trp genotype and 25 with Trp64Arg genotype of
论文类型:
基础研究
论文编号:
doi: 10.1111/j.1365-2125.2009.03431.x.
学科门类:
临床医学
文献类型:
J
卷号:
68
期号:
1
页面范围:
14-22
ISSN号:
doi: 10.1111/j.1365-2125.2009.03431.x.
是否译文:
否
附件: